Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a major complication of hematopoietic stem cell transplantation (HSCT) associated with high morbidity and mortality [1 –3]. TA-TMA is characterized by endothelial damage consisting of microangiopathic hemolytic anemia and microvascular thrombosis, leading to tissue ischemia and organ damage [4–7]. In TA-TMA, complement activation and endothelial damage can be triggered by multiple insults after transplantation, including chemotherapy, total body irradiation (TBI), HLA mismatch, calcineurin inhibitor (CNI) therapy, graft-versus-host disease (GVHD), and viral infections [3,8,9].

Source: Biology of Blood and Marrow Transplantation - March 21, 2024 Category: Hematology Authors: MI Ben ítez-Carabante, D. Bueno, L. Alonso García, I. López Torija, J. Marsal, JM Fernandez Navarro, ML Uria Oficialdegui, M. Panesso, B. Molina, C. Beléndez Bieler, P. Palomo, A. Pérez Martínez, C. Diaz-de-Heredia Tags: Full Length Article Source Type: research